Abstract
Ovarian Cancer (OC) is a most lethal female malignancy worldwide, mostly due to the late‐stage diagnosis and high recurrence rate. Survival statistics remain stuck at ~30% for the past four decades highlighting the necessity to improve the early stage detection and therapeutic outcomes. Nanotherapy in OC may provide significant and unique benefits for drug efficacy as well as for reducing the therapeutically limiting adverse effects associated with current treatment regimens. Herein, we report a unique nanoparticle (NP)‐based platform of peptide‐stabilized poly (lactic‐co‐glycolic acid) (PLGA). The ultimate goal is NP‐mediated targeted delivery of anticancer therapy and contrast agents. Morphology and small size (~100 nm) of NPs provide them an ideal candidate for mechanistic studies. We present detailed imaging studies of NPs uptake by OC cells as well as NPs distribution within cellular organelles obtained with high resolution live cell imaging. The results show a preferential accumulation of NPs in mitochondria. In addition, the in vitro studies include the NP‐based delivery of anticancer agents, such as Pt(II) and mitochondria‐targeting lonidamine. This project demonstrates potential of peptide‐stabilized nanocarrier as an effective nanomedicine against cancer. The PLGA is FDA approved and the amino acids of the peptides have Generally Regarded as Safe (GRAS) status. The NP platform is completely biodegradable, and as we demonstrate biologically active.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
